Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron - Evidence summary new medicine (ESNM69)
Information type: Evidence summaries
Source: National Institute for Health
Specialities: Cancers | Gastrointestinal disorders
Summary
This evidence summary, based on two phase III RCTs, discusses the best available evidence on the safety and efficacy of netupitant/palonosetron capsules (Akynzeo), which were launched in the UK in Sept 2015.
UKMi comment
The product is licensed in adults for the:

• prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy.
• prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.
Related links:

Prevention of chemotherapy induced nausea and vomiting in adults: netupitant/palonosetron - Evidence summary new medicine (ESNM69)